BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

195 related articles for article (PubMed ID: 33506327)

  • 21. Dabrafenib plus trametinib in patients with previously treated BRAF(V600E)-mutant metastatic non-small cell lung cancer: an open-label, multicentre phase 2 trial.
    Planchard D; Besse B; Groen HJM; Souquet PJ; Quoix E; Baik CS; Barlesi F; Kim TM; Mazieres J; Novello S; Rigas JR; Upalawanna A; D'Amelio AM; Zhang P; Mookerjee B; Johnson BE
    Lancet Oncol; 2016 Jul; 17(7):984-993. PubMed ID: 27283860
    [TBL] [Abstract][Full Text] [Related]  

  • 22. SMARCA4-deficient undifferentiated uterine sarcoma (malignant rhabdoid tumor of the uterus): a clinicopathologic entity distinct from undifferentiated carcinoma.
    Kolin DL; Dong F; Baltay M; Lindeman N; MacConaill L; Nucci MR; Crum CP; Howitt BE
    Mod Pathol; 2018 Sep; 31(9):1442-1456. PubMed ID: 29700418
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Using whole genome amplification (WGA) of low-volume biopsies to assess the prognostic role of EGFR, KRAS, p53, and CMET mutations in advanced-stage non-small cell lung cancer (NSCLC).
    Lim EH; Zhang SL; Li JL; Yap WS; Howe TC; Tan BP; Lee YS; Wong D; Khoo KL; Seto KY; Tan L; Agasthian T; Koong HN; Tam J; Tan C; Caleb M; Chang A; Ng A; Tan P
    J Thorac Oncol; 2009 Jan; 4(1):12-21. PubMed ID: 19096301
    [TBL] [Abstract][Full Text] [Related]  

  • 24. SWI/SNF-deficient thoraco-pulmonary neoplasms.
    Sesboue C; Le Loarer F
    Semin Diagn Pathol; 2021 May; 38(3):183-194. PubMed ID: 33451916
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Detection of PIK3CA mutations, including a novel mutation of V344G in exon 4, in metastatic lung adenocarcinomas: A retrospective study of 115 FNA cases.
    Allison DB; Lilo MT; Geddes S; Pallavajjalla A; Askin F; Gabrielson E; Zheng G; Li QK
    Cancer Cytopathol; 2016 Jul; 124(7):485-92. PubMed ID: 27007084
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Pancreatic undifferentiated rhabdoid carcinoma: KRAS alterations and SMARCB1 expression status define two subtypes.
    Agaimy A; Haller F; Frohnauer J; Schaefer IM; Ströbel P; Hartmann A; Stoehr R; Klöppel G
    Mod Pathol; 2015 Feb; 28(2):248-60. PubMed ID: 25103069
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Biological markers and DNA flow cytometric analysis in radically resected patients with non-small cell lung cancer. A study of the Perugia Multidisciplinary Team for Thoracic Tumors.
    Ludovini V; Pistola L; Gregorc V; Floriani I; Rulli E; Di Carlo L; Semeraro A; Daddi G; Darwish S; Stocchi L; Tofanetti FR; Bellezza G; Sidoni A; Tognellini R; Crinò L; Tonato M
    Tumori; 2008; 94(3):398-405. PubMed ID: 18705409
    [TBL] [Abstract][Full Text] [Related]  

  • 28. SMARCB1 (INI1)-negative rhabdoid carcinomas of the gastrointestinal tract: clinicopathologic and molecular study of a highly aggressive variant with literature review.
    Agaimy A; Rau TT; Hartmann A; Stoehr R
    Am J Surg Pathol; 2014 Jul; 38(7):910-20. PubMed ID: 24503755
    [TBL] [Abstract][Full Text] [Related]  

  • 29. SWI/SNF Complex-deficient Undifferentiated Carcinoma of the Gastrointestinal Tract: Clinicopathologic Study of 30 Cases With an Emphasis on Variable Morphology, Immune Features, and the Prognostic Significance of Different SMARCA4 and SMARCA2 Subunit Deficiencies.
    Chang B; Sheng W; Wang L; Zhu X; Tan C; Ni S; Weng W; Huang D; Wang J
    Am J Surg Pathol; 2022 Jul; 46(7):889-906. PubMed ID: 34812766
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Loss of switch/sucrose non-fermenting complex protein expression in undifferentiated gastrointestinal and pancreatic carcinomas.
    Tessier-Cloutier B; Schaeffer DF; Bacani J; Marginean CE; Kalloger S; Köbel M; Lee CH
    Histopathology; 2020 Jul; 77(1):46-54. PubMed ID: 32413172
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Anaplastic Lymphoma Kinase (ALK)-positive Tumors: Clinical, Radiographic and Molecular Profiles, and Uncommon Sites of Metastases in Patients With Lung Adenocarcinoma.
    Gupta R; Amanam I; Rahmanuddin S; Mambetsariev I; Wang Y; Huang C; Reckamp K; Vora L; Salgia R
    Am J Clin Oncol; 2019 Apr; 42(4):337-344. PubMed ID: 30741758
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Sensitive methods for screening of the MEK1 gene mutations in patients with central nervous system metastases of non-small cell lung cancer.
    Nicoś M; Krawczyk P; Jarosz B; Sawicki M; Michnar M; Trojanowski T; Milanowski J
    Clin Transl Oncol; 2016 Oct; 18(10):1039-43. PubMed ID: 26860843
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Comprehensive molecular analysis of driver mutations in non-small cell lung carcinomas and its correlation with PD-L1 expression, An Indian perspective.
    Aggarwal A; Sharma S; Brar Z; Kumar V; Kumar A; Katara R; Mohanty SK
    Pathol Res Pract; 2024 Jan; 253():155013. PubMed ID: 38096714
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Clinicopathological and prognostic significance of SWI/SNF complex subunits in undifferentiated gastric carcinoma.
    Zhang Z; Li Q; Sun S; Li Z; Cui ZG; Zhang M; Liu Q; Zhang Y; Xiong S; Zhang S
    World J Surg Oncol; 2022 Dec; 20(1):383. PubMed ID: 36464671
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Screening for EGFR and KRAS mutations in endobronchial ultrasound derived transbronchial needle aspirates in non-small cell lung cancer using COLD-PCR.
    Santis G; Angell R; Nickless G; Quinn A; Herbert A; Cane P; Spicer J; Breen R; McLean E; Tobal K
    PLoS One; 2011; 6(9):e25191. PubMed ID: 21949883
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Defining the first bona fide cell model for SMARCA4-deficient, undifferentiated tumor.
    Arenas AM; Ruiz-Jiménez JM; López-Hidalgo JL; Sanjuán-Hidalgo J; Medina PP
    J Pathol; 2023 Sep; 261(1):5-10. PubMed ID: 37352131
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Characteristics and Outcomes of Patients with Lung Cancer Harboring Multiple Molecular Alterations: Results from the IFCT Study Biomarkers France.
    Guibert N; Barlesi F; Descourt R; Léna H; Besse B; Beau-Faller M; Mosser J; Pichon E; Merlio JP; Ouafik L; Guichard F; Mastroianni B; Moreau L; Wdowik A; Sabourin JC; Lemoine A; Missy P; Langlais A; Moro-Sibilot D; Mazières J
    J Thorac Oncol; 2017 Jun; 12(6):963-973. PubMed ID: 28189832
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Loss of switch/sucrose non-fermenting complex protein expression is associated with dedifferentiation in endometrial carcinomas.
    Karnezis AN; Hoang LN; Coatham M; Ravn S; Almadani N; Tessier-Cloutier B; Irving J; Meng B; Li X; Chow C; McAlpine J; Kuo KT; Mao TL; Djordjevic B; Soslow RA; Huntsman DG; Blake Gilks C; Köbel M; Lee CH
    Mod Pathol; 2016 Mar; 29(3):302-14. PubMed ID: 26743474
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Clinicopathological characteristics of gastric SMARCA4-deficient undifferentiated/rhabdoid carcinoma].
    Wu JY; Jiang K; Yan LJ; Yin LS; Huang XZ; Jia L; Sun Y
    Zhonghua Bing Li Xue Za Zhi; 2023 May; 52(5):447-453. PubMed ID: 37106285
    [No Abstract]   [Full Text] [Related]  

  • 40. The Landscape of Actionable Molecular Alterations in Immunomarker-Defined Large-Cell Carcinoma of the Lung.
    Chan AW; Chau SL; Tong JH; Chow C; Kwan JSH; Chung LY; Lung RW; Tong CY; Tin EK; Law PP; Law WT; Ng CSH; Wan IYP; Mok TSK; To KF
    J Thorac Oncol; 2019 Jul; 14(7):1213-1222. PubMed ID: 30978501
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.